MOTS-c is a mitochondrial-derived peptide investigated in studies of metabolic signalling and cellular stress responses. The questions in that literature are distinct from the specification of a vial sold under the same name. This overview explains selected research papers and how to read their evidence; Core Research materials are supplied for in-vitro laboratory research, not human or veterinary use.

What is MOTS-c?

Lee and colleagues described a short open reading frame within mitochondrial 12S rRNA associated with a 16-amino-acid peptide called MOTS-c. Their paper proposed a signalling role involving the folate/purine pathways and AMPK, a regulator of cellular energy status. These are research findings, not a claim that a commercial preparation has a demonstrated human application. [1]

An open reading frame is a stretch of genetic sequence that can encode a peptide or protein. The important research question here is not simply whether mitochondria produce energy, but whether a peptide associated with their genome participates in communication and metabolic regulation.

A chemical specification answers a different question: which exact material is present in a particular preparation? That requires the applicable sequence and form documentation, not an inference from the name MOTS-c.

Three papers, different questions

Paper	Question and model	Finding to interpret	Limit of that evidence
Lee et al., 2015 [1]	MOTS-c identity and metabolic signalling, with cellular and mouse experiments.	Connections between folate/purine metabolism, AMPK and the measured metabolic endpoints.	These experimental findings do not establish the characteristics of a supplied vial or a human intervention.
Kim et al., 2018 [2]	Nuclear gene regulation under metabolic stress in cell-based work.	AMPK-dependent nuclear localisation and interaction with stress-responsive gene regulation.	A cellular mechanism is not evidence that every downstream endpoint will change in every model.
Reynolds et al., 2021 [3]	Separate human exercise observations and experimental work in cells and mice.	Endogenous MOTS-c changed with exercise in the human component; the administered-peptide work was a different experimental component.	The human exercise observations are not a trial of people receiving a commercial MOTS-c preparation.

This is a selected-paper orientation, not a systematic review or a claim that every current study has been assessed. It excludes administration protocols and therapeutic selection.

Metabolic signalling is not one universal mechanism

Lee and colleagues linked MOTS-c to inhibition of the folate cycle and associated purine synthesis in their cellular work, with AMPK activation. They also reported changes in insulin sensitivity in mouse models. These are different layers of evidence: the cell work explores a biochemical pathway, while the mouse work asks an organism-level question. Neither establishes a human-use indication. [1]

A pathway observation is not the same as a direct molecular interaction. An observation downstream of AMPK does not, by itself, show that AMPK is the peptide’s direct binding target.

A useful reading note records the measured endpoint rather than replacing it with a broader slogan. Ask what was compared, what changed, and which part of the causal explanation the experiment actually tested. This keeps mechanistic interpretation separate from a claim about the whole organism or an unrelated product.

What does the nuclear-localisation paper add?

Kim and colleagues reported that MOTS-c moved to the nucleus following metabolic stress and influenced nuclear gene expression. The work includes glucose restriction and interaction with antioxidant-response regulation, including NRF2. It adds a gene-regulation question to the metabolic literature; it is not a human efficacy study. [2]

Localisation, gene expression and a functional outcome are different measurements. Evidence for one can motivate investigation of another, but should not be silently substituted for it. A report that a peptide is detected in the nucleus needs to be read alongside the experimental controls and the endpoint being claimed.

Why the human exercise observations need careful wording

Reynolds and colleagues measured naturally occurring MOTS-c in human muscle and circulation around exercise. The study also contains separate cell and mouse experiments. The human component does not show what happens when people receive a supplied MOTS-c product. [3]

That distinction is easy to lose when an article is summarised as a single “human and animal study”. Each component must retain its own exposure, comparison and outcome. Observing an endogenous signal during exercise is not equivalent to demonstrating an administered preparation’s clinical effect.

How to compare a new paper with these studies

Use the same questions for each paper rather than treating all mentions of MOTS-c as equivalent evidence.

Check	Why it matters
Exact material	The named entity, sequence, terminal form and formulation need to match the question.
Model	A cell system, an animal experiment and a human observation answer different questions.
Exposure	Endogenous measurement and experimental addition are not the same design.
Comparator	Identify the control and what it can separate from the proposed peptide effect.
Endpoint	Keep a molecular measurement distinct from a functional or clinical conclusion.
Uncertainty	Read variability, controls and limitations before generalising.
Independence	Several papers from overlapping author groups are not automatically independent replications.

This table is an editorial reading framework, not a reported result from a new Core Research experiment.

What the literature cannot tell you about a supplied batch

A research paper is not a Certificate of Analysis for a commercial lot. It does not establish that a supplied vial has the same composition, purity profile, handling history or formulation as the material used by the authors.

For material assessment, use Batch Documentation and the CoA-reading guide. Read chemical-form details in the source specification and the analytical report together. A sequence label, a nominal molecular mass and an MS ion assignment should not be treated as interchangeable descriptions.

For handling questions, use the MOTS-c laboratory handling reference alongside the documentation applicable to the material and your institutional procedure. This overview does not prescribe a solvent, storage period or experimental preparation method.

Related catalogue records

The MOTS-c 40mg vial, 40mg refill and 40mg pen-format item are separate catalogue records for in-vitro laboratory research. Their product pages concern the supplied presentation and purchasing conditions, not a promise of the findings discussed above. Not for human or veterinary use.

For wider context, see the metabolic research comparison, the Metabolic & NAD+ catalogue and Testing & Quality Methodology.

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. DOI: 10.1016/j.cmet.2015.02.009.
2. Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018. DOI: 10.1016/j.cmet.2018.06.008.
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. DOI: 10.1038/s41467-020-20790-0.